Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

MLA

Robert Benamouzig, et al. “Efficacy and Safety of Pasireotide-LAR for the Treatment of Refractory Bleeding Due to Gastrointestinal Angiodysplasias: Results of the ANGIOPAS Multicenter Phase II Noncomparative Prospective Double-Blinded Randomized Study.” Therapeutic Advances in Gastroenterology, vol. 11, Feb. 2018. EBSCOhost, https://doi.org/10.1177/1756283X18756260.

APA

Robert Benamouzig, Mourad Benallaoua, Jean-Christophe Saurin, Marouane Boubaya, Christophe Cellier, René Laugier, Magalie Vincent, Christian Boustière, Rodica Gincul, Elia Samaha, Philippe Grandval, Thomas Aparicio, Gheorghe Airinei, Bakhtiar Bejou, Cyriaque Bon, Jean-Jacques Raynaud, Vincent Levy, & Denis Sautereau. (2018). Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. Therapeutic Advances in Gastroenterology, 11. https://doi.org/10.1177/1756283X18756260

Chicago

Robert Benamouzig, Mourad Benallaoua, Jean-Christophe Saurin, Marouane Boubaya, Christophe Cellier, René Laugier, Magalie Vincent, et al. 2018. “Efficacy and Safety of Pasireotide-LAR for the Treatment of Refractory Bleeding Due to Gastrointestinal Angiodysplasias: Results of the ANGIOPAS Multicenter Phase II Noncomparative Prospective Double-Blinded Randomized Study.” Therapeutic Advances in Gastroenterology 11 (February). doi:10.1177/1756283X18756260.